Cartesian Therapeutics, Inc.

RNACNASDAQHealthcare● Active

$5.86

+$0.02(+0.34%)

Market Cap$172175590

P/E Ratio—

52W High$15.57

52W Low$5.6

Avg Volume217K

Open$6.00

Beta0.78

Net Income Financials Revenue

Cartesian Therapeutics, Inc. (RNAC) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

RNAC · net income · updated Jun 9, 2026

Core profitability metrics

RNAC · net income · margin · TTM · CAGR

Net income was −$130.3M for FY2025 (fiscal year ending 2025-12-31), down 68.3% year-over-year. Net profit margin was -4658.6%. Based on available data, Cartesian Therapeutics, Inc. has been profitable since at least 2022.

FY2025 Net Income−$130.3M▼ -68.3% YoY

Trailing 12M (TTM)−$151.8Mtrailing 4 quarters sum

Net Profit Margin< −999%−$130.3M ÷ $2.8M

YoY Change-68.3%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2022

▸ FMP /income-statement · Annual · RNAC net income history · RNAC profit margin

Annual net income data

RNAC · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$130.3M▼ 68.3%-4658.6%$2.8M

FY2024Loss−$77.4M▲ +64.8%-199.0%$38.9M

FY2023Loss−$219.7M▼ 721.0%-844.9%$26.0M

FY2022★ First Profit$35.4M▲ +237.7%31.9%$110.8M

FY2021Loss−$25.7M▲ +62.7%-30.2%$85.1M

Net income vs peers (Healthcare)

RNAC vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

Cartesian Therapeutics, Inc.YOU

RNAC

−$130.3M-68.3%-4658.6%

Loss

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Cartesian Therapeutics, Inc. (RNAC) reported net income of −$130.3M for FY2025 (fiscal year ending 2025-12-31), down 68.3% year-over-year. The net profit margin was -4658.6% — meaning the company kept $-46.59 of every dollar of revenue as profit.

Based on available data, Cartesian Therapeutics, Inc. has been profitable since at least 2022. Net income reached a peak of $35.4M in FY2022. Data available for 12 fiscal years.

Cartesian Therapeutics, Inc.'s net profit margin was -4658.6% for FY2025, based on the latest annual results.

Investors sometimes search for "Cartesian Therapeutics, Inc. net worth" — the company's market capitalization is a separate figure from RNAC net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

RNAC net income · 4 questions

Cartesian Therapeutics, Inc. is not currently profitable on an annual basis. The company reported a net loss of $130.3M for FY2025.

is RNAC profitabledoes RNAC make a profitRNAC profitabilityRNAC profitable company

▸ Source: FMP /income-statement · GAAP · Cartesian Therapeutics, Inc. · Cartesian Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026